Four-Drug attack on blood cancer shows promise in early trial

This study is testing a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. The main goal is to see how many patients achieve a deep remission (complete response) after the initial treatment phase. After this, treatment decisions will be guided by whether tiny amounts of leftover cancer cells can be detected, aiming for better long-term control of the disease.